Rexahn Pharmaceutical Inc.’s chief executive officer saw a 23 percent decrease in total compensation in the company’s 2016 fiscal year due to a decrease in stock awards, according to a Securities and Exchange Commission filing.
Peter D. Suzdak’s total compensation for the fiscal year totaled $824,091, down from $1.0 million in the company’s 2015 fiscal year. His stock awards declined to $229,581 in fiscal year 2016 from $629,484 in fiscal year 2015.
Suzdak’s salary for fiscal year 2016 was $430,000, the same from his fiscal year 2015 base salary.
Rexahn, which is a clinical stage biopharmaceutical company focused on developing therapeutics for the treatment of cancer, reported no revenue in its 2016 and 2015 fiscal years.
Rexahn’s annual meeting will be Tuesday, April 11, at 8 a.m. Eastern time, at the Radisson Hotel, located at 3 Research Court in Rockville.
The company’s shares closed Feb. 13 at 28 cents, up 6 cents.
